15:53:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-29 Bokslutskommuniké 2024
2024-10-29 Kvartalsrapport 2024-Q3
2024-07-30 Kvartalsrapport 2024-Q2
2024-05-17 Ordinarie utdelning ZICC 0.00 SEK
2024-04-29 Kvartalsrapport 2024-Q1
2024-01-26 Bokslutskommuniké 2023
2023-10-25 Kvartalsrapport 2023-Q3
2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2023-10-23 08:30:00

Ziccum AB (publ) has received data from external contract research (CRO) partner Truly Labs, confirming high activity levels in mRNA/LNP materials dried by LaminarPace, after continued internal confirmations. The in-vitro data validate the ability of Ziccum’s LaminarPace technology to transform delicate mRNA/LNP solution into stable, bioactive dry powder with excellent in-vitro characteristics.

The external confirmation and extended data set of preserved mRNA activity after LaminarPace treatment was obtained with cell-based in-vitro assays by the CRO. The study was performed to validate the internal mRNA activity data previously reported on March 20th. The new data give a clear and distinctive confirmation of the ability of Ziccum’s LaminarPace technology to transform delicate mRNA/LNP solution into stable, bioactive dry powder with excellent in-vitro characteristics.

mRNA is one of the three target vaccine platforms Ziccum focuses on, and its in-house mRNA project is of central strategic importance, considering the market need and growth. In October 2022, Ziccum reported proof of successful nebulization and drying of a vaccine/LNP model substance. In March 2023, Ziccum reported the same positive confirmations regarding encapsulation and particle properties for actual mRNA/LNP trials, plus confirmed mRNA activity after LaminarPace drying and reconstitution to liquid. These findings have since then been repeatedly confirmed in continued internal studies. The new CRO activity read-outs are obtained in a different mRNA model - and having the same clear activity preservation in a second mRNA model makes the validation stronger.

Ziccum has recently signed two major agreements for Evaluation Studies on mRNA/LNP treatment with LaminarPace – the first in May with a leading Biopharmaceutical corporation, the second in July with a multinational Pharmaceutical corporation. These collaborations also will include in-vitro activity readouts.

CEO Ann Gidner: “Investment and innovation in RNA and mRNA therapies continue to grow and the industry efforts are very impressive. Solutions for stability and delivery that can enable new vaccine and drug projects could broadly expand the possibilities for this booming therapeutic platform. These distinct mRNA activity results for Ziccum constitute excellent and important confirmation. The next step is the in-vivo data, to see this confirmed in animal models. This work is starting now”.